source
- Celcuity waits on FDA review of second plant as cancer drug rollout lags expectationsCelcuity has announced that it is awaiting the U.S. Food and Drug Administration’s review of a second manufacturing facility needed for its newly approved cancer therapy. The company explained tha…
- Becton Dickinson recalls intraosseous needle sets over risk of obturator removal difficultyBecton Dickinson has issued a recall for specific intraosseous vascular access system needle sets after discovering that the obturator (stylet) can be difficult to remove once the device is placed.…